Price T Rowe Associates Inc. MD Has $1.41 Million Holdings in Alector, Inc. (NASDAQ:ALEC)

Price T Rowe Associates Inc. MD decreased its position in shares of Alector, Inc. (NASDAQ:ALEC) by 8.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 746,088 shares of the company’s stock after selling 70,370 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.76% of Alector worth $1,411,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Barclays PLC boosted its position in Alector by 132.4% during the third quarter. Barclays PLC now owns 176,800 shares of the company’s stock valued at $824,000 after acquiring an additional 100,731 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Alector by 64.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company’s stock valued at $12,716,000 after purchasing an additional 1,072,298 shares in the last quarter. Nordea Investment Management AB grew its stake in Alector by 5.1% during the fourth quarter. Nordea Investment Management AB now owns 165,713 shares of the company’s stock worth $295,000 after purchasing an additional 7,971 shares during the period. SG Americas Securities LLC increased its holdings in Alector by 27.9% in the fourth quarter. SG Americas Securities LLC now owns 39,334 shares of the company’s stock worth $74,000 after purchasing an additional 8,581 shares in the last quarter. Finally, Apollon Wealth Management LLC acquired a new position in Alector in the fourth quarter valued at approximately $47,000. 85.83% of the stock is owned by institutional investors.

Alector Price Performance

NASDAQ:ALEC opened at $1.18 on Friday. Alector, Inc. has a one year low of $0.87 and a one year high of $6.78. The company has a market cap of $117.49 million, a PE ratio of -0.69 and a beta of 0.76. The firm has a 50-day moving average of $1.19 and a 200-day moving average of $2.12.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.59. The firm had revenue of $54.24 million during the quarter, compared to the consensus estimate of $20.41 million. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. On average, equities research analysts expect that Alector, Inc. will post -1.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ALEC has been the subject of several recent analyst reports. HC Wainwright raised their price objective on shares of Alector from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday. Morgan Stanley reissued an “underweight” rating and set a $1.50 price objective (down previously from $3.00) on shares of Alector in a research report on Friday, March 7th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Alector presently has an average rating of “Hold” and a consensus target price of $4.00.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.